The Effects of Belsomra on Alzheimer's Patients

Belsomra has shown promise in improving sleep quality in Alzheimer's patients. Additionally, it has demonstrated potential for enhancing cognitive function and reducing behavioral changes associated with the disease. However, further research is needed to explore its interaction with other medications, as well as its long-term effects and safety profile. Identifying these considerations and addressing research gaps will help guide future studies and improve the understanding of Belsomra's effects on Alzheimer's patients.

Overview of Belsomra

Mechanism of Action

Belsomra functions by targeting orexin receptors in the brain which govern sleep-wakefulness effects. Through inhibiting these receptors, Belsomra may enhance sleep in Alzheimer's sufferers. The pill, approved for insomnia, is witnessed to decrease destructive proteins linked to Alzheimer's, making it crucial to comprehend the long-term impact and safety while taking Belsomra.

Dosage and Administration

Administration of Belsomra to Alzheimer's patients necessitates precise guidelines to ensure the safe and efficacious utilization of the drug. A daily oral dose of 5 mg just before sleep is recommended. Note that Belsomra may affect alertness, so it should only be taken if 7-8 hours of sleep can follow. Dosage may require adjustment based on patient response, overall health, and age. Strict adherence not to surpass a 10 mg maximum daily dose is paramount.

Common Side Effects

Potential side effects include daytime drowsiness, possibly heightening risk of falls and injuries. Confusion, which may exacerbate the cognitive decline inherent in Alzheimer's, was also reported along with mood shifts, such as agitation or aggression. It's crucial to consider these when assigning Belsomra, given their potential impact on Alzheimer's patients' quality of life. Further studies are necessary to fully assess potential long-term effects, safety, and possible drug interactions in this population.

Impact of Belsomra on Alzheimer's Patients

Sleep Quality Improvement

Belsomra has demonstrated its ability to better sleep efficiency and decrease the duration Alzheimer's patients take to fall asleep. Signs of the drug minimizing sleep disturbances and nocturnal awakenings have also been noted. This sleep improvement potentially benefits the patient's general wellbeing and brain functionality. However, further investigations are necessary to encapsulate the drug's total effect on sleep quality among this demographic, and its correlation with other Alzheimer's medication.

Cognitive Function Enhancement

Belsomra exhibits encouraging results in improving cognitive functions among Alzheimer's patients. The medicine has been linked to enhanced memory, attention, overall cognitive performance and even executive functioning abilities such as decision-making and problem-solving. Its use has also indicated potential in reducing cognitive decline, thereby delaying Alzheimer's progress. These results propose that Belsomra could be crucial in managing cognitive deficits linked to Alzheimer's, hence elevating the affected individuals' quality of life. However, more studies are needed to understand the long-term impacts and safety parameters of Belsomra in this specific group. They could also help uncover information gaps and identify areas requiring further investigation.

Behavioral Changes

Belsomra has shown potential in mitigating behavioral changes such as agitation, aggression, and irritability seen in Alzheimer's patients. Such improvements could greatly enhance the quality of life for patients and those caring for them. However, it's essential to be mindful of the potential drug interactions with other Alzheimer's medications. Additionally, the long-term impact and safety of using Belsomra within this patient group require further exploration. Further studies are also required to fully comprehend Belsomra's effect on behavioral adjustments within Alzheimer's patients and to identify potential knowledge gaps.

Considerations and Future Directions

The interplay between Belsomra and other approved medications in Alzheimer's patients poses significant consideration for its implementation in dementia care. Delving into the prospective effects, risks, and countered benefits of combining Belsomra with other routinely employed drugs for such patients is indispensable. Furthermore, investigating the enduring influence on safety and potential adverse effects of Belsomra in Alzheimer's patients is of paramount importance. This investigation necessitates a thorough comprehension of any potential harmful effects while weighing-in the possible long-term advantages. Conclusively, there exist vital areas of research that demand attention to broaden our understanding of Belsomra's implications on individuals diagnosed with Alzheimer's disease. Recognising these areas of research and unaddressed gaps will add significant inputs to our collective knowledge and understanding of Belsomra's clinical efficacy in this demographic.

Bibliography

Muehlan, C., Vaillant, C., & Zenklusen..., I. (2020). Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert opinion on ...(https://www.tandfonline.com/doi/abs/10.1080/17425255.2020.1817380)
Clark, J. W., Brian, M. L., Drummond, S. P. A., & Hoyer..., D. (2020). Effects of orexin receptor antagonism on human sleep architecture: a systematic review. Sleep Medicine ...(https://www.researchgate.net/profile/Maddison-Brian/publication/341361137_Effects_of_orexin_receptor_antagonism_on_human_sleep_architecture_A_systematic_review/links/6295542ec660ab61f853dceb/Effects-of-orexin-receptor-antagonism-on-human-sleep-architecture-A-systematic-review.pdf)
Jacobson, L. H. & Hoyer..., D. (2022). Hypocretins (orexins): The ultimate translational neuropeptides. Journal of Internal ...(https://onlinelibrary.wiley.com/doi/pdf/10.1111/joim.13406)
Asai, Y., Sano, H., Miyazaki, M., Iwakura, M., & Maeda..., Y. (2019). Suvorexant (Belsomra® Tablets 10, 15, and 20 mg): Japanese Drug-Use Results Survey. Drugs in R&D. (https://link.springer.com/article/10.1007/s40268-018-0256-6)
Roth, T. & Brunton, S. (2019). Identification and management of insomnia in Alzheimer's disease. J Fam Pract. (https://cdn.mdedge.com/files/s3fs-public/jfp_hot_topics_2019_revised_insomnia_10.29.pdf)
"Clinical Efficacy for BELSOMRA® (Suvorexant) in Patients with Insomnia and Mild to Moderate Alzheimer's Disease (AD)." Belsomra-Hcp, 23 Oct. 2023, (https://www.merckconnect.com/belsomra/insomnia-in-mild-to-moderate-alzheimers-disease/)
"Insomnia Drug May Lower Levels of Alzheimer's Proteins." National Institutes of Health (NIH), 9 May 2023, (https://www.nih.gov/news-events/nih-research-matters/insomnia-drug-may-lower-levels-alzheimer-s-proteins)
‌Celmer, Lynn. "FDA Updates Insomnia Medication Info to Include Alzheimer's Study." American Academy of Sleep Medicine -- Association for Sleep Clinicians and Researchers, 7 Feb. 2020, (https://aasm.org/fda-updates-insomnia-medication-info-to-include-alzheimers-study/)